in this issue
Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals
Lonza Signs Manufacturing Agreement with U.S. Biopharma Firm
10:06 AM MDT | May 29, 2009 | DEEPTI RAMESH
Lonza says it has entered into a manufacturing services agreement with biopharmaceutical firm Morphotek (Exton, PA), to support the development and manufacturing of a subset of antibodies in Morphotek’s therapeutics pipeline. Lonza will reserve capacity for commercial manufacturing of Morphotek’s lead compound farletuzumab, which recently entered Phase III clinical trials for ovarian cancer, under the deal. Sijbesma: Strength in life sciences units. Morphotek, a subsidiary of pharma company Eisai (Woodcliff Lake, NJ), specializes in the development of...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee